Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer-Reference-Cited by-同舟云学术

Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer

Published:2018-07 Issue: Volume:121 Page:5-11
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Nie Keke,Zhang Zhongfa,Zhang Chunling,Geng Chuanxin,Zhang Ling,Xu Xiajuan,Liu Shichao,Wang Songping,Zhuang Xingjun,Lan Ketao,Ji Youxin^ORCID

Funder

National Health and Family Planning Commission of Peoples Republic of China

Medical Technology Research Center for Health Development

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference28 articles.

1. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies;Yu;Cancer Res.,2007

2. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor;Kobayashi;Cancer Res.,2005

3. EGFR T790M mutation: a double role in lung cancer cell survival?;Suda;J. Thorac. Oncol.,2009

4. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer;Janne;N. Engl. J. Med.,2015

5. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer;Jiang;Transl. Lung Cancer Res.,2014

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meta-analysis of Targeted Therapies in EGFR-mutated Non–Small Cell Lung Cancer;American Journal of Clinical Oncology;2024-09-11

2. Osimerinib haematological toxicities in non-small cell lung cancer: a randomised controlled trials meta-analysis;BMJ Supportive & Palliative Care;2024-08-19

3. Dual-target EZH2 inhibitor: latest advances in medicinal chemistry;Future Medicinal Chemistry;2024-07-31

4. Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis;Targeted Oncology;2024-06-01

5. Analyses of quality of life in cancer drug trials - a review of measurements and analytical choices in post-reimbursement studies;BMC Cancer;2024-03-06